The Innovation of a Targeted Oral Peptide in Moderate to Severe Plaque Psoriasis
- This event has passed.
The Innovation of a Targeted Oral Peptide in Moderate to Severe Plaque Psoriasis
Speaker: Eingun James Song, MD, FAAD Board-certified Dermatologist Co-Chief Medical Officer Director of Clinical Research Frontier Dermatology Pacific Northwest Dr Song is a board-certified dermatologist, Co-Chief Medical Officer, and Director of Clinical Research for Frontier Dermatology in the Pacific Northwest. He is clinical instructor at the University of Washington and is a nationally recognized key opinion leader in psoriasis, atopic dermatitis, and hidradenitis suppurativa.
Moderator: Leon Kircik, MD, FAAD Medical Director, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai, New York, NY Indiana University Medical Center, Indianapolis, IN Medical Director Physicians Skin Care, PLLC, Louisville, KY DermResearch, PLLC, Louisville, KY Skin Sciences, PLLC, Louisville, KY
Please join us for our next IDF Educational Series Webinar: The Innovation of a Targeted Oral Peptide in Moderate to Severe Plaque Psoriasis PROGRAM OBJECTIVES 1. Review unmet need in psoriasis 2. Introduce ICOTYDE mechanism of action 3. Discuss key safety and efficacy results from the ICONIC clinical trial program ICOTYDE is the first and only IL-23 receptor-targeted oral peptide in a once-daily pill for moderate to severe plaque psoriasis in adults and pediatric patients 12 years of age and older weighing at least 40 kg.